SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending amid community discussion around its potential as 'the new Bitcoin' and increased institutional interest, particularly following investments from figures like the Winklevoss twins. Conversations highlight ZEC's privacy features and limited supply, with some suggesting a significant shift from Bitcoin to Zcash. Bullish sentiment is tempered by concerns about volatility and potential corrections.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the crypto community discusses its potential breakout, referencing patterns observed in Zcash's previous run. Bullish sentiment is fueled by the anticipation of a government reopening and the LTCN ETF, with some eyeing price targets in the hundreds. Technical analysis chatter includes inverted head and shoulders patterns and golden cross formations, suggesting a possible surge if key resistance levels are breached.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst heightened speculation and community chatter surrounding the release of Epstein files and their potential implications for the company and its figureheads. The community is actively dissecting alleged connections and potential fallouts, while some voice concerns about the company's financial performance. Political narratives and partisan bickering continue to fuel the conversation around the stock.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending as investors discuss upcoming earnings and the company's potential for profitability, with some anticipating a positive report. Community members are also highlighting XPEV's expansion into robotics and AI, seeing it as more than just an EV company and comparing its progress to competitors. Bullish sentiment seems to be growing, although some concerns about cash flow and potential dilution remain.

The community has officially TAKEN OVER $HIPPO - after the dev threw in the towel! The cutest $HIPPO on SUI is now powered by a full CTO. No cats, no dogs. Only $HIPPO, driven by the people, for the people! $HIPPO is ready to break out stronger than ever!  Su Deng is the cutest $HIPPO on SUI, bringing $HIPPO to the world of memes.  $HIPPO - No cats, no dogs Only hippo!  We are donating a % of our profits to wildlife needs across the world. Starting with support for Khao Kheow Open Zoo, the zoo that houses Moo Deng

sudeng

HIPPO (sudeng) is experiencing increased attention, with community members actively discussing potential pumps and anticipating a comeback. The conversation includes speculation about market influences, recent price drops, and comparisons to other meme coins in the SUI ecosystem, generating both excitement and questions about its future.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending amid discussions about its partnership with Vaxart for an oral COVID-19 vaccine, a potential game-changer in vaccine delivery. The community is weighing the implications of institutional ownership, share buybacks, and a proxy fight involving Deep Track Capital. Some are speculating on potential buyout scenarios and the future direction of Dynavax's strategic partnerships.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amidst lowered sales guidance for 2025, despite a recent revenue beat and expansion of a U.S. Army contract, triggering debate about management's credibility and future prospects. Community discussions revolve around the impact of government delays and the potential for a strong 2026, with some expressing concerns about the company's leadership and others seeing a buying opportunity. The drone sector's overall growth potential remains a key talking point.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is trending due to news of a potential reverse split, leading to discussions about its impact on the ETF and investor returns. Community members are also weighing in on recent dividend payouts and strategizing around reinvestment and potential trading opportunities. Some are expressing concerns about NAV erosion and comparing TSLY to other high-yield ETFs.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind (MNKD) is trending due to community discussion around the company's leadership and strategic decisions, particularly regarding CEO Mike Castagna. Debate centers on past agreements, product commercialization, and the potential for a merger or acquisition. Bullish sentiment exists based on analyst upgrades and future growth prospects, while others express concerns about the company's performance and direction.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amidst discussions about upcoming earnings and its potential growth compared to competitors like Starbucks. Community members are weighing factors such as tariff reductions, expansion strategies, and consumer spending habits, while some debate the stock's valuation and potential price movement. Bullish sentiment is building towards earnings, though concerns about consumer spending and the overall economic climate remain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.</li><li>Cidara’s CD388 flu antibody, now in phase 3 trials with FDA breakthrough status, has driven significant takeover interest.</li><li>Retail traders debated whether the move signals a full buyout or a milestone-based deal structure.</li></ul><p>Cidara Therapeutics’ shares surged 42% after hours on Thursday following reports that Merck is close to acquiring the biotech in a deal that could be announced as soon as Friday.&nbsp;</p><p>The negotiations reportedly extended late into Thursday as Merck competed with another pharmaceutical group before the seller ultimately favored its offer. The deal is expected to value Cidara above its roughly $3.3 billion market capitalization, though the final price has apparently not been set. Any agreement is likely to include upfront cash and milestone-based payments tied to clinical progress, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae">report</a> by Financial Times.</p><h2 class="st-heading-2"><strong>Big Pharma Races To Rebuild Pipelines</strong></h2><p>A potential takeover would mark Merck’s latest move to fortify its drug portfolio before Keytruda, its $25 billion-per-year cancer therapy, loses patent protection in 2028. The company agreed in July to buy respiratory drug developer Verona Pharma for $10 billion as part of a broader effort to maintain revenue momentum. The demand for Cidara comes after another big-name auction last week, when&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci">Pfizer narrowly won a race against Novo Nordisk</a> for obesity biotech Metsera in a deal worth as much as $10 billion.</p><h2 class="st-heading-2"><strong>Biotech Sector Heats Up As M&amp;A Wave Accelerates</strong></h2><p>The race for Cidara is unfolding amid a surge in biotechnology dealmaking.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The XBI biotech index</a> has gained over 40% in the past six months as investors bet on a return of acquisitions by big drugmakers looking to add next-generation therapies to their pipelines. The scramble reflects rising urgency across the sector as companies face major revenue losses once key products lose exclusivity.</p><h2 class="st-heading-2"><strong>Cidara’s Lead Flu Antibody Drives Takeover Expectations</strong></h2><p>Cidara’s value surge is tied to its lead program, CD388, a long-acting antibody intended to protect against the two most common strains of influenza. The treatment is being evaluated in phase 3 trials among immunosuppressed patients who cannot receive vaccines, as well as healthy adults over 65. Over 6,000 patients are expected to be enrolled in the studies worldwide by the end of the month. CD388 has been granted an&nbsp;FDA breakthrough designation, which could accelerate regulatory approval. Cidara’s shares have quadrupled since July, driven by strong clinical data and takeover speculation that have fueled investor expectations.</p><h2 class="st-heading-2"><strong>Stocktwits Buzz Highlights Takeover Speculation</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both stocks seeing ‘high’ message volume.</p><p>One user reacted to the report by saying, “sounds like $MRK going in for the kill.”</p><p><stembedurl>https://stocktwits.com/JFais/message/636148828</stembedurl></p><p>Another user questioned the structure of the potential deal, writing, “It makes me wonder if it is an actual buyout or an investment in the company for rights to their drug? It mentions the possibility of upfront cash plus milestone payments.... hopefully it is a buyout above the current $150 AH price.”</p><p><stembedurl>https://stocktwits.com/PooPooPewPew/message/636148400</stembedurl></p><p>While&nbsp;<a href="https://stocktwits.com/symbol/CDTX">Cidara’s stock</a> has surged 446% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merk’s stock</a> has risen 18% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.

Equity

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks 

Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.

Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth. 

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Verona Pharma Plc - ADR

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

VRNA
Verona Pharma Plc American Depositary

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VRNA News

VRNAVerona Pharma Plc American Depositary